Ozempic & NAION: What Australia's TGA Warning About GLP-1 Drugs and Bl – Good Machine

TL;DR

Australia's Therapeutic Goods Administration (TGA) issued a class-wide safety warning on 23 July 2026 linking GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda — to non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe eye disorder that can cause sudden, permanent vision loss.
The Australian database of adverse events has recorded 36 cases: 23 linked to semaglutide (Ozempic/Wegovy), 10 to tirzepatide (Mounjaro), and 3 to liraglutide (Saxenda).
The TGA states bluntly: "no treatment has been shown to improve visual acuity outcomes" once NAION develops.
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) reached the same conclusion, classifying NAION as a "very rare side effect" of semaglutide medicines.
This is not a recall. It is not a withdrawal. It is a product information update — and the distinction matters enormously for the millions of Australians currently taking these drugs.

What Happened

On 23 July 2026, the TGA updated the Product Information (PI) and Consumer Medicine Information (CMI) documents for every GLP-1 receptor agonist marketed in Australia. The update adds a warning about non-arteritic anterior ischaemic optic neuropathy — NAION, pronounced "nay-on" — a condition in which blood flow to the optic nerve is suddenly disrupted, causing painless vision loss that is typically permanent and almost always affects only one eye.

The regulator first flagged the potential association in July 2024, following a study published in JAMA Ophthalmology that found higher-than-expected rates of NAION among semaglutide users. Since then, the TGA has been monitoring Australian cases, analysing reports from overseas regulators, and consulting with its Advisory Committee on Medicines.

The trigger for the July 2026 update was the accumulation of sufficient evidence to warrant a formal warning — not a single new study, but a pattern that had become too consistent to ignore. The European Medicines Agency's PRAC concluded its own investigation and classified NAION as a "very rare side effect" of semaglutide medicines (Ozempic, Rybelsus, Wegovy). The UK's MHRA issued a parallel drug safety update. Australia's TGA is now the latest major regulator to act.

The warning covers the entire GLP-1 RA class: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), dulaglutide (Trulicity), and liraglutide (Saxenda). The TGA's database of adverse events contains 36 Australian cases. Twenty-three involve semaglutide. Ten involve tirzepatide. Three involve liraglutide.

The language in the updated product information is unambiguous: NAION "may result in permanent visual impairment, including blindness, and no treatment has been shown to improve visual acuity outcomes." Patients are advised to seek immediate medical attention if they experience any sudden vision loss.

What It Actually Means

The story here is not "Ozempic causes blindness." The story is about how we weigh rare but catastrophic risks against well-established benefits — and who gets to do the weighing.

The numbers, placed in context. Thirty-six Australian cases. As of early 2026, an estimated 400,000 to 500,000 Australians were prescribed GLP-1 RAs — the exact figure is hard to pin down because Ozempic prescribing for off-label weight loss has been widespread and poorly tracked. At the midpoint of that range, 36 cases represents roughly 0.008% of users. That is eight cases per 100,000 — firmly in "very rare" territory, consistent with the EMA's classification.

But "very rare" does not mean "zero." And for the 36 people who woke up one morning unable to see out of one eye, the denominator is irrelevant.

The mechanism is not confirmed. The TGA has not established that GLP-1 RAs cause NAION. The relationship is an association — a statistical signal in adverse event reporting and observational studies. The JAMA Ophthalmology study that first raised the alarm in 2024 was a retrospective cohort study, not a randomised controlled trial. It can show correlation; it cannot prove causation.

There are plausible biological mechanisms. GLP-1 receptors are expressed in the optic nerve. Rapid improvements in glycaemic control — which GLP-1 RAs produce — can temporarily worsen diabetic retinopathy, a phenomenon already documented with these drugs. NAION is known to be associated with diabetes, hypertension, sleep apnoea, and the "disc at risk" optic nerve anatomy — all of which are more common in the population taking GLP-1 RAs. Disentangling the drug effect from the underlying disease effect is genuinely difficult.

The TGA acknowledges this. The warning says the drugs "have the potential to cause" NAION — not that they do cause it. The product information notes that "some studies suggest an increased risk" and that there is "no identified time interval" for when NAION might develop after starting treatment. This is calibrated language from a regulator that knows the evidence is suggestive but not definitive.

The treatment problem. Once NAION occurs, there is no treatment. Not "limited treatment options." Not "treatment under investigation." No treatment. The optic nerve infarcts. The tissue dies. Vision does not come back. This is what makes the risk-benefit calculus different from, say, nausea or constipation — side effects that are unpleasant but reversible. NAION is a one-way door.

The Hype Deconstruction

The headlines have been predictable: "Ozempic linked to blindness." "Urgent warning over popular weight-loss drugs." "Eye stroke risk from diabetes medication." These are not false — the TGA did issue a warning, and NAION can cause blindness. But they compress a complex risk signal into a binary scare, and the compression does real harm.

Here is what the headlines leave out:

The absolute risk is very low. Thirty-six cases in a user population of hundreds of thousands. For most patients, the risk of NAION from GLP-1 RAs is substantially lower than the risk of cardiovascular events, kidney failure, or vision loss from poorly controlled diabetes — the very outcomes these drugs prevent.

The alternative is not risk-free. Uncontrolled type 2 diabetes causes diabetic retinopathy, which is a leading cause of blindness in working-age adults. Obesity is associated with idiopathic intracranial hypertension, which can also cause vision loss. Removing a patient from a GLP-1 RA because of NAION risk without addressing the underlying condition is not a neutral decision.

The signal is being taken seriously by regulators — which is how the system is supposed to work. The TGA identified a potential association in July 2024, monitored it for two years, consulted with international counterparts, and updated the product information when the evidence crossed a threshold. This is pharmacovigilance functioning as designed. It is not a failure. It is not a cover-up. It is the boring, essential work of making medicines safer over time.

Novo Nordisk and Eli Lilly are not denying the signal. Novo Nordisk's statement — "patient safety is a top priority" and "we continuously monitor the safety profile of our medicines" — is standard corporate language, but the company has not disputed the TGA's findings. The product information updates were made in collaboration with the sponsors. This is not a case of a regulator forcing a reluctant company to act.

Stakeholder Landscape

Patients currently taking GLP-1 RAs (directly affected): roughly half a million Australians. The TGA's advice is to be alert for sudden vision loss and to seek immediate medical attention if it occurs. The advice is not to stop taking the medication. Patients who are concerned should discuss the risk with their prescribing doctor — and that conversation should include the risks of stopping treatment, not just the risks of continuing.

Prescribing doctors (directly affected): the patient conversation just got harder. Every GLP-1 RA prescription now carries a documented risk of permanent blindness, however rare. Informed consent requires disclosing that risk. The challenge is communicating "very rare but catastrophic" in a way that is accurate without being alarmist — and doing it in a 15-minute consultation.

Optometrists and ophthalmologists (second-order): the TGA notes that people with a "disc at risk" optic nerve anatomy are more susceptible to NAION, and that this can be assessed by an optometrist or ophthalmologist. This creates a potential screening pathway — but it is not yet standardised, not yet reimbursed, and not yet clear whether screening actually reduces risk. Expect professional societies to issue guidance in the coming months.

Novo Nordisk and Eli Lilly (commercial exposure): the financial risk is modest. NAION is very rare. The warning is a product information update, not a recall or a restriction. But the reputational risk is real — GLP-1 RAs have been positioned as near-miracle drugs, and a documented risk of permanent blindness complicates that narrative. The class is also facing scrutiny on other safety signals, including a possible association with suicidal ideation (under EMA review) and the known risk of pancreatitis.

The "natural" and "holistic" wellness industry (beneficiaries of the noise): every safety warning about GLP-1 RAs is marketing fuel for the supplement, "metabolic health," and "food as medicine" sectors. Expect NAION to feature prominently in Instagram posts selling berberine, inositol, and "natural Ozempic alternatives" — none of which have been tested for efficacy or safety at the scale of GLP-1 RAs, and none of which carry the same pharmacovigilance infrastructure that just caught the NAION signal.

The general public (second-order): the risk of NAION from GLP-1 RAs is not a reason to avoid these drugs if you need them. It is a reason to pay attention to sudden vision changes and to have the conversation with your doctor. The bigger public health risk is that fear-driven discontinuation leads to worse outcomes from the underlying conditions these drugs treat.

Cross-Layer Implications

The pharmacovigilance layer. The NAION signal was first detected through a retrospective observational study, not through a randomised controlled trial. RCTs are powered for efficacy, not for rare adverse events. This is a case study in why post-market surveillance matters — and why regulators need well-funded adverse event reporting systems that can detect signals in populations of millions, not thousands.

The regulatory coordination layer. The TGA, EMA, and MHRA all reached similar conclusions within a similar timeframe. This is not always the case — regulatory fragmentation is common, and patients in different countries often receive different safety information about the same drug. The NAION warning is an example of regulatory coordination working. It is also a reminder that the FDA has not yet issued an equivalent class-wide warning, though individual product labels in the US do reference NAION risk.

The patient-autonomy layer. The hardest question in pharmacovigilance is not "does this drug cause this side effect?" It is "who gets to decide whether the risk is worth it?" The TGA's approach — update the label, inform prescribers, let patients and doctors decide — is the standard model. It assumes that patients, armed with accurate information, can weigh rare catastrophic risks against tangible daily benefits. Whether that assumption holds when the information reaches patients through alarmist headlines rather than through a conversation with their doctor is a different question.

The obesity-treatment layer. GLP-1 RAs are in the process of being recommended as long-term treatments for obesity by the World Health Organization. Every safety signal — NAION, suicidal ideation, pancreatitis — will be scrutinised in that context. The question is not whether these drugs have risks. All drugs have risks. The question is whether the risk-benefit balance supports long-term use in a population that is orders of magnitude larger than the type 2 diabetes population for which the drugs were originally developed.

What This Means for You

If you are taking a GLP-1 RA (Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda): do not stop taking your medication based on this warning. The absolute risk of NAION is very low. The risks of uncontrolled diabetes or rapid weight regain are well-established and significant. What you should do: be aware that sudden, painless vision loss in one eye — typically noticed upon waking — is a medical emergency that requires immediate ophthalmological assessment. If it happens, go to an emergency department or an eye hospital. Do not wait to see if it resolves. It probably will not.

If you are considering starting a GLP-1 RA: the NAION risk should be part of the informed consent conversation with your doctor. Ask about your individual risk factors: diabetes, hypertension, high cholesterol, sleep apnoea, smoking, and whether you have a "disc at risk" optic nerve anatomy. If you have multiple risk factors, discuss whether a baseline eye examination — including optic nerve assessment — is appropriate before starting treatment.

If you are a prescribing doctor: update your informed consent process to include NAION. The key points: very rare (roughly 8 per 100,000 users in Australian data), typically sudden and painless, usually unilateral, no proven treatment once it occurs, and patients with pre-existing cardiovascular risk factors or "disc at risk" anatomy may be at higher baseline risk. Consider recommending a baseline optometric examination for patients with multiple risk factors. Document the discussion.

If you are an optometrist or ophthalmologist: you are about to see patients asking whether their optic nerves put them at risk. The "disc at risk" — a small, crowded optic nerve head with a small or absent physiological cup — is a well-established risk factor for NAION independent of GLP-1 RA use. Whether GLP-1 RAs amplify that risk is unknown. What you can do: identify patients with disc-at-risk anatomy, inform them of the baseline NAION risk (which exists regardless of medication), and advise them to report any sudden vision changes immediately.

For everyone else: this is not a reason to fear GLP-1 RAs. It is a reason to respect them. These are powerful drugs with real side effects, some of which are only becoming apparent as millions of people take them for years. The pharmacovigilance system is working — it detected a rare signal, investigated it, and updated the label. That is how drug safety is supposed to function. The fact that the signal exists does not mean the drugs are dangerous. It means we are paying attention.

Uncertainty Ledger

Causation vs. association. The TGA has not established that GLP-1 RAs cause NAION. The evidence is observational. A randomised controlled trial powered to detect NAION would need to be impractically large. The causal question may never be definitively resolved.
Mechanism. If GLP-1 RAs do cause NAION, the mechanism is unknown. Plausible candidates include haemodynamic changes, effects on retinal autoregulation, and the known phenomenon of rapid glycaemic improvement temporarily worsening diabetic eye disease. Understanding the mechanism would help identify which patients are at highest risk.
Class effect vs. agent-specific. The TGA warning covers the entire GLP-1 RA class, but the case counts are dominated by semaglutide (23 of 36 Australian cases). This could reflect a true difference in risk between agents, or it could simply reflect that semaglutide is the most prescribed drug in the class. Tirzepatide (Mounjaro) has a shorter market history; its NAION risk profile is less well-characterised.
Screening utility. The TGA notes that disc-at-risk anatomy can be assessed by an eye care professional, but there is no evidence that screening reduces NAION risk. A patient with disc-at-risk anatomy who is not taking a GLP-1 RA already has an elevated baseline risk of NAION. Whether GLP-1 RAs add to that risk — and whether screening changes outcomes — is unknown.
FDA action. The FDA has not issued a class-wide warning equivalent to the TGA's. Individual US product labels reference NAION, but the regulatory posture differs. Whether the FDA will follow the EMA, MHRA, and TGA with a formal class-wide update is uncertain.
Long-term risk with long-term use. GLP-1 RAs are increasingly prescribed for years or decades. The NAION signal has been detected in a population with relatively short exposure history. Whether the risk accumulates with duration of use is unknown.

Bottom Line

The TGA has linked GLP-1 receptor agonists to 36 Australian cases of a rare eye disorder that can cause sudden, permanent blindness — and has updated every product label to reflect that risk. The absolute risk is very low, roughly 8 cases per 100,000 users. The alternative — uncontrolled diabetes or obesity — carries its own well-documented risks to vision. This is not a recall, not a reason to stop treatment, and not a scandal. It is pharmacovigilance doing its job: detecting a rare signal, investigating it, and giving patients and doctors the information they need to make an informed choice. The system worked. Now the hard part — communicating "very rare but catastrophic" without causing panic or driving patients away from drugs that are, on balance, saving far more vision than they threaten — begins.

Sources

Therapeutic Goods Administration, "GLP-1 RAs and rare vision disorder," Safety Alert, 23 July 2026. [Tier 1 — national regulator]
ABC News (Australia), "TGA issues warning over GLP-1-based drugs' potential to cause rare eye disorder," 25 July 2026. [Tier 1 — national broadcaster]
The Guardian Australia, "Australian regulator TGA warns of 'rare but severe' eye disorder linked to GLP-1 drugs like Ozempic," 24 July 2026. [Tier 1 — established outlet]
7NEWS Australia, "New warning for Ozempic, Wegovy and Mounjaro over serious eye disorder including blindness," 24 July 2026. [Tier 2 — national news]
European Medicines Agency, PRAC conclusion on NAION and semaglutide medicines (referenced by TGA). [Tier 1 — EU regulator]
JAMA Ophthalmology, Hathaway JT et al., "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," 2024; 142(8):732-739. [Tier 1 — peer-reviewed]
UK MHRA, Drug Safety Update: Semaglutide and risk of NAION (referenced by TGA). [Tier 1 — UK regulator]
The West Australian, "TGA issues new warning after finding link between GLP-1 medicines to eye disorder," 25 July 2026. [Tier 2 — regional outlet]
The Senior, "TGA: Ozempic users warned of rare vision loss condition," 24 July 2026. [Tier 3 — specialist audience outlet]
Acumen, "Australia's TGA Issues Critical Class-Wide Safety Warning for Ozempic and Mounjaro," 25 July 2026. [Tier 3 — news briefing service]